Whether your personal interests are in supporting innovation, bringing lifesaving biomedical products to patients, training the next generation of biomedical leaders or fueling our economy, the Center for Biotechnology provides a vehicle to accomplish great things. Things that matter. Things that change, and save, lives.
Your involvement is an essential part of our future. Please consider a gift to the Center for Biotechnology which will help fuel innovation by ensuring that lifesaving technologies make it out of research labs and into the hands of patients.
Give to the Center for Biotechnology online through the Stony Brook Foundation. Contributions can be made to our Fund for Excellence. More information about donating through the Stony Brook Foundation can be found here.
Farmingdale, New York based Codagenix, Inc., a clinical-stage biotechnology company developing prophylactic vaccines and oncolytic virus therapies, has announced the closing of a $20 million Series B investment round.
The new investment was led by Adjuvant Capital, with participation by Euclidean Capital and Topspin Partners. The funds will be used to support the further clinical development of Codagenix’s live attenuated RSV vaccine for the elderly, a broadly-protective influenza vaccine and an oncolytic virus therapy for triple negative breast cancer (TNBC).
This funding round, combined with Series A investments, brings Codagenix’s total funding to $38 million. Previous funders include Topspin Partners, the Center for Biotechnology and various U.S. government agencies. More.
The Center for Biotechnology is pleased to announce a request for proposals for our Research Evaluation and Commercialization Hub (REACH) award program. Awards will be in two categories: Feasibility ($50k/12mo) and Proof of Concept ($100K/12 mo.) Details on the full funding program overview and proposal guidelines can be found here.
The development of promising innovations often stalls due to limited early-stage funding to address translational uncertainties. The Center for Biotechnology's Research Evaluation and Commercialization Hub (REACH) award program bridges the translation gap between biomedical discovery and their development toward commercial goals. Program funding is intended to determine feasibility, develop proof-of-concept, and ultimately lead to follow-on funding, a strategic partnership, or company formation.
The REACH program supports faculty and postdoctoral researchers in translating bio-based, bio-convergence, and bio-medical research discoveries by providing targeted funding and strategic guidance to bridge the translation gap between discovery and development for commercialization.
[post_title] => Funding Opportunity: Research Evaluation and Commercialization Hub (REACH)Awards
[post_excerpt] => The Center for Biotechnology is pleased to announce a request for proposals for our REACH award program. Awards will be in two categories: Feasibility ($50k/12mo) and Proof of Concept ($100K/12 mo.)
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => news-reach25
[to_ping] =>
[pinged] =>
[post_modified] => 2025-03-24 12:11:36
[post_modified_gmt] => 2025-03-24 16:11:36
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=4804
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[1] => WP_Post Object
(
[ID] => 4488
[post_author] => 4
[post_date] => 2024-10-24 10:45:00
[post_date_gmt] => 2024-10-24 14:45:00
[post_content] =>
Governor Kathy Hochul has unveiled plans for New York BioGenesis Park, a groundbreaking $430 million Cell and Gene Therapy (CGT) Innovation Hub in Nassau County, Long Island. To be developed by The Albanese Organization, Inc., this state-of-the-art facility would catalyze CGT research, development, clinical manufacturing, and commercialization across New York State. With a historic $150 million state investment—the largest nationwide for a cell and gene therapy hub—NYBGP would accelerate the delivery of new therapies from lab to patient in New York's diverse communities. This transformative hub aims to establish New York as the leading global destination for CGT innovation, driving economic growth, attracting top talent, and revolutionizing patient care statewide and beyond.
The Center for Biotechnology is thrilled to be counted as a partner in this effort, and is looking forward to working with our colleagues in the initiative to help catalyze and accelerate life-changing therapies.
New York BioGenesis Park is envisioned as a cutting-edge, full-service campus dedicated to advancing cell and gene therapies and accelerating their commercialization. At full build-out, the 700,000-square-foot park would create an end-to-end Cell and Gene Therapy innovation and supply center, featuring interconnected areas for public engagement, research, manufacturing, and collaboration.
A cornerstone of New York BioGenesis Park is its incubator, supported by a $50 million investment from ESD's Long Island Investment Fund. This facility will empower early-stage therapeutic developers by offering state-of-the-art wet lab space, shared equipment, office space, and other essential resources. This nurturing environment will provide Cell and Gene Therapy companies with access to specialized equipment, mentoring, and stage-appropriate financial guidance. As a critical component of New York BioGenesis Park, the incubator is poised to catalyze the growth of promising Cell and Gene Therapy companies by providing them with resources and support, unlocking their potential for innovation and success.
New York BioGenesis Park would foster strong ties with academic and medical institutions throughout New York, creating a robust ecosystem for Cell and Gene Therapy innovation. Collaborating with the Empire State Cellular Therapy Consortium and world-class institutions like Cold Spring Harbor Laboratory, the Feinstein Institutes, Northwell Health, Roswell Park, Stony Brook University, Weill Cornell, Columbia University and others around the state, New York BioGenesis Park would enhance research synergies and accelerate medical breakthroughs. This ecosystem would bring together experts in advanced Cell and Gene Therapy therapies, offering specialized facilities, services, and resources to both tenants and collaborating institutions. By facilitating cutting-edge science, innovative technology development and novel approaches to clinical trials, New York BioGenesis Park would ensure New York's institutions remain globally competitive in groundbreaking Cell and Gene Therapy research and commercialization.
[post_title] => Long Island to be location for Nation-Leading Cell and Gene Therapy Innovation Hub: New York BioGenesis Park.
[post_excerpt] =>
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => long-island-to-be-location-for-nation-leading-cell-and-gene-therapy-innovation-hub-new-york-biogenesis-park
[to_ping] =>
[pinged] =>
[post_modified] => 2025-02-26 16:35:20
[post_modified_gmt] => 2025-02-26 21:35:20
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=4488
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[2] => WP_Post Object
(
[ID] => 1930
[post_author] => 1
[post_date] => 2016-02-24 21:38:31
[post_date_gmt] => 2016-02-24 21:38:31
[post_content] =>
The State University of New York’s Blog, Big Ideas, recently published a post featuring highlighting the Long Island Bioscience Hub and how it is working with federal support to transform biomedical research into next-generation medical solutions. Read the post here.
[post_title] => SUNY’s Big Idea Blog Features Long Island Bioscience Hub
[post_excerpt] => The State University of New York’s Blog, Big Ideas, recently published a post featuring highlighting the Long Island Bioscience Hub
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => sunys-big-idea-blog-features-long-island-bioscience-hub
[to_ping] =>
[pinged] =>
[post_modified] => 2016-03-29 20:29:25
[post_modified_gmt] => 2016-03-29 20:29:25
[post_content_filtered] =>
[post_parent] => 0
[guid] => http://centerforbiotechnology.org/new/?p=1930
[menu_order] => 189
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[3] => WP_Post Object
(
[ID] => 3446
[post_author] => 3
[post_date] => 2020-02-19 15:19:33
[post_date_gmt] => 2020-02-19 15:19:33
[post_content] => Health Innovation Hub Life Science by Springboard Enterprises
Applications for the Health Innovation Hub: Life Science are open through February 24.Springboard’s Health Innovation Hub: Life Science is a program for women-led life science and healthcare companies seeking growth funding and connections to experts and strategic partners for product development and expansion. Selected Hub companies are matched with a personal advisory team, tasked with providing a meaningful impact on the company’s next stage of growth. The program, while virtual, engages advisors and investors in a variety of in-person presentation sessions throughout the year and beyond.
Areas of focus for the program include (but are not limited to) drugs, therapeutics, diagnostics, medtech, and medical devices. Our 2020 Health Hub programming has a special focus on Women's Health Innovation. Cost: $200 application fee ($100 is submitted by the priority deadline). If accepted: $5,000 program fee. Learn more here: sb.co/hih , Application Link Here
If you are interested or would like to refer an entrepreneur, please contact Sierra Hieronymus: sierra@sb.co
[post_title] => Health Innovation Hub Life Science - Applications Open
[post_excerpt] =>
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => health-innovation-hub-life-science-applications-open
[to_ping] =>
[pinged] =>
[post_modified] => 2020-02-19 15:19:33
[post_modified_gmt] => 2020-02-19 15:19:33
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=3446
[menu_order] => 75
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[4] => WP_Post Object
(
[ID] => 4426
[post_author] => 4
[post_date] => 2024-05-21 14:27:18
[post_date_gmt] => 2024-05-21 18:27:18
[post_content] =>
The Life Sciences Innovation and Entrepreneurship (LiSIE) program at Stony Brook is looking to give students a jump-start in the bioscience industry. The program is a joint effort between the Department of Biomedical Engineering in the College of Engineering and Applied Sciences, the College of Business and the Center for Biotechnology. “From the lab to leadership”, the program aims to teach key business principles to life sciences students so they’re equipped to work in the business side of science.
Read the recent SBU News feature on the program and the CFB Appointed Director Director of the Program in Life Sciences Innovation and Entrepreneurship, Dr. Louis A. Peña.
The Center for Biotechnology is pleased to announce a request for proposals for our Research Evaluation and Commercialization Hub (REACH) award program. Awards will be in two categories: Feasibility ($50k/12mo) and Proof of Concept ($100K/12 mo.) Details on the full funding program overview and proposal guidelines can be found here.
The development of promising innovations often stalls due to limited early-stage funding to address translational uncertainties. The Center for Biotechnology's Research Evaluation and Commercialization Hub (REACH) award program bridges the translation gap between biomedical discovery and their development toward commercial goals. Program funding is intended to determine feasibility, develop proof-of-concept, and ultimately lead to follow-on funding, a strategic partnership, or company formation.
The REACH program supports faculty and postdoctoral researchers in translating bio-based, bio-convergence, and bio-medical research discoveries by providing targeted funding and strategic guidance to bridge the translation gap between discovery and development for commercialization.
